Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* female participants, age \>/=18 years~* advanced, inflammatory or early stage unilateral invasive breast cancer~* HER2-positive breast cancer~* baseline left ventricular ejection fraction (LVEF) \>/=55%~Exclusion Criteria:~* metastatic disease (Stage IV) or bilateral breast cancer~* previous anticancer therapy or radiotherapy for any malignancy~* other malignancy, except for carcinoma in situ of the cervix, or basal cell carcinoma~* clinically relevant cardiovascular disease~* current chronic treatment with corticosteroids of \>10mg methylprednisolone or equivalent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T+P Concomitant Anthracycline-based chemotherapy (Type: EXPERIMENTAL): 5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
- T+P Sequential Anthracycline-based chemotherapy (Type: EXPERIMENTAL): FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
- T+P Concomitant Non-Anthracycline chemotherapy (Type: EXPERIMENTAL): Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).